Founded in 2022, être Venture Capital is a women-led venture capital firm based in Santa Cruz, California. It focuses on investing in early-stage startups owned by minorities and women, as well as seed-stage critical technologies developed by diverse teams in the US. The firm aims to foster an inclusive VC ecosystem and provide education for various stakeholders.
Hexas Biomass specializes in producing sustainable non-wood biomass derived from a high-yielding perennial crop that can grow in diverse climates with minimal inputs. This nature-based substitute is designed to supplement and replace traditional wood, food crops used for fuel, and fossil fuel-based feedstocks across various industries. The company's primary goal is to facilitate the production of eco-friendly alternatives ranging from fiberboard to sustainable packaging to biofuels, thereby enabling clients to reduce their reliance on wood and petroleum-based materials.
Portico Wellness
Venture Round in 2022
Portico Wellness operates a platform that connects employees with independent mental health professionals, including psychologists, social workers, and therapists, as well as related integrative service providers. The service enables users to search for providers, contact them, and schedule appointments, while employing health data management to verify credentials and support informed care decisions. By integrating with employee compensation benefits, Portico Wellness helps organizations offer accessible behavioral health and wellness services tailored to individual needs, aiming to improve engagement and outcomes for employees.
Obatala Sciences
Series A in 2022
Obatala Sciences is a biotechnology company focused on developing an innovative in vitro humanized adipose tissue model system aimed at addressing the significant economic burden of obesity and diabetes. By treating body fat as a functional organ, the company seeks to enhance the understanding of its role in health and disease. Their three-dimensional screening tool simplifies tissue engineering, facilitating disease modeling, cell assays, cell identification, tissue analysis, and drug discovery. This model enables academic and pharmaceutical researchers to efficiently identify effective drug compounds, ultimately reducing the time, cost, and effort associated with testing potential treatments for obesity, diabetes, other metabolic diseases, and related cancers.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.